Clinical experience with aztreonam in four Mediterranean countries

Area of Science:

• Pharmacology and Microbiology
• Infectious Diseases

Background:

• Aztreonam is a synthetic monobactam beta-lactam antibiotic.
• It exhibits specific activity against aerobic gram-negative bacteria.

Purpose of the Study:

• To evaluate the efficacy and tolerability of aztreonam in patients with serious gram-negative infections.
• To assess the eradication rates of aerobic gram-negative bacteria, including Pseudomonas aeruginosa, from various infection sites.

Main Methods:

• Parenteral administration of aztreonam at doses of 1-8 g per day.
• Analysis of bacterial isolates from urinary tract infections and other sites.
• Assessment of clinical signs and symptoms resolution.

Main Results:

• 93% of gram-negative organisms from urinary tract infections were eradicated.
• 86% of Pseudomonas aeruginosa strains from urinary sites were eradicated.
• 86% of gram-negative organisms from other infection sites were eradicated, with similar patient symptom resolution across all sites.
• Aztreonam was well-tolerated both locally and systemically.

Conclusions:

• Aztreonam is an effective antibiotic for treating serious aerobic gram-negative bacterial infections.
• It shows high efficacy in eradicating pathogens, including Pseudomonas aeruginosa.
• The antibiotic is well-tolerated, making it a viable treatment option.